Cross‐sectional study of patients with VCP multisystem proteinopathy 1 using dual‐energy x‐ray absorptiometry
Muscle & Nerve · 2024
DOI: 10.1002/mus.28095 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Rod Carlo Agram Columbres und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of California, Irvine, California, USA. Hauptthemen laut MEDLINE: Absorptiometry, Photon, Bone Density, Myositis, Inclusion Body, Osteitis Deformans. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAMS NIH HHS, FDA HHS, Office of Extramural Research.
Abstract (Originalsprache)
Introduction/Aims VCP multisystem proteinopathy 1 (MSP1), encompassing inclusion body myopathy (IBM), Paget's disease of bone (PDB) and frontotemporal dementia (FTD) (IBMPFD), features progressive muscle weakness, fatty infiltration, and disorganized bone structure in Pagetic bones. The aim of this study is to utilize dual‐energy x‐ray absorptiometry (DXA) parameters to examine it as a biomarker of muscle and bone disease in MSP1.
Methods
DXA scans were obtained in 28 patients to assess body composition parameters (bone mineral density [BMD], T ‐score, total fat, and lean mass) across different groups: total VCP disease ( n = 19), including myopathy without Paget's (“myopathy”; n = 12) and myopathy with Paget's (“Paget”; n = 7), and unaffected first‐degree relatives serving as controls ( n = 6).
Results
In the VCP disease group, significant declines in left hip BMD and Z ‐scores were noted versus the control group ( p ≤ .03). The VCP disease group showed decreased whole body lean mass % ( p = .04), and increased total body fat % ( p = .04) compared to controls. Subgroup comparisons indicated osteopenia in 33.3% and osteoporosis in 8.3% of the myopathy group, with 14.3% exhibiting osteopenia in the Paget group. Moreover, the Paget group displayed higher lumbar L1‐L4 T ‐score values than the myopathy group.
Discussion
In MSP1, DXA revealed reduced bone and lean mass, and increased fat mass. These DXA insights could aid in monitoring disease progression of muscle loss and secondary osteopenia/osteoporosis in MSP1, providing value both clinically and in clinical research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genetics and Metabolism, Department of Pediatrics, School of Medicine, University of California, Irvine, California, USA.
- College of Osteopathic Medicine, William Carey University, Hattiesburg, Mississippi, USA.
- College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, California, USA.
- Department of Neurology, School of Medicine, University of California, Irvine, California, USA.
- Department of Pathology, School of Medicine, University of California, Irvine, California, USA.
ORCID-Profile: Virginia Kimonis
Förderung
- NIAMS NIH HHS
- FDA HHS
- Office of Extramural Research
Zitieren
APA
Columbres, R. C. A., Luu, V., Nguyen, M., & Kimonis, V. (2024). Cross‐sectional study of patients with VCP multisystem proteinopathy 1 using dual‐energy x‐ray absorptiometry. Muscle & Nerve. https://doi.org/10.1002/mus.28095
Vancouver
Columbres RCA, Luu V, Nguyen M, Kimonis V. Cross‐sectional study of patients with VCP multisystem proteinopathy 1 using dual‐energy x‐ray absorptiometry. Muscle & Nerve. 2024. doi:10.1002/mus.28095
BibTeX
@article{Columbres2024,
author = {Columbres, Rod Carlo Agram and Luu, Vu and Nguyen, Minh and Kimonis, Virginia},
title = {Cross‐sectional study of patients with VCP multisystem proteinopathy 1 using dual‐energy x‐ray absorptiometry},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28095}
}
EUVIMED